Tiger Brokers

BUZZ-CG Oncology jumps after late-stage bladder cancer therapy data

Reuters
Apr 28
BUZZ-CG Oncology jumps after late-stage bladder cancer therapy data

** Shares of cancer drug developer CG Oncology CGON.O rise 34% to $30

** On late Saturday, CGON said its bladder cancer therapy, cretostimogene grenadenorepvec, showed 42.3% of patients maintained complete response at 24 months for high-risk bladder cancer patients who failed previous treatments, in an ongoing late-stage study

** 97.3% of treated patients remained free from progression to more serious muscle-invasive bladder cancer at 24 months, co said

** Early data from another patient group, Cohort P, showed 90.5% of patients remained free from high-grade recurrence at both 3 and 9 months

** As of last close, stock down 22% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10